Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2
- PMID: 23539753
- DOI: 10.1136/jmedgenet-2013-101607
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2
Abstract
Background: Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
Patients and methods: A prospective study involving women seen at a single family history clinic in Manchester, UK. Patients were excluded if they had ovarian cancer or oophorectomy prior to clinic. Follow-up was censored at the latest date of: 31/12/2010; ovarian cancer diagnosis; oophorectomy; or death. We used person-years at risk to assess ovarian cancer rates in the study population, subdivided by genetic status (BRCA1, BRCA2, BRCA negative, BRCA untested) compared with the general population.
Results: We studied 8005 women from 895 families. Women from BRCA2 mutation families showed a 17-fold increased risk of invasive ovarian cancer (relative risk (RR) 16.67; 95% CI 5.41 to 38.89). This risk increased to 50-fold in women from families with BRCA1 mutations (RR 50.00; 95% CI 26.62 to 85.50). No association was found for women in families tested negative for BRCA1/2, where there was 1 observed invasive ovarian cancer in 1613 women when 2.74 were expected (RR 0.37; 95% CI 0.01 to 2.03). There was no association with ovarian cancer in families untested for BRCA1/2 (RR 0.99; 95% CI 0.45 to 1.88).
Discussion: This study showed no increased risk of ovarian cancer in families that tested negative for BRCA1/2 or were untested. These data help counselling women from BRCA1/2 negative families with breast cancer that their risk of invasive ovarian cancer is not higher than the general population.
Keywords: BRCA; Cancer: breast; Cancer: ovarian.
Comment in
-
BRCA1/2 negative status predicts no extended risk of invasive ovarian cancer.Clin Genet. 2014 Jan;85(1):17-8. doi: 10.1111/cge.12303. Epub 2013 Nov 14. Clin Genet. 2014. PMID: 24134137 No abstract available.
Similar articles
-
Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.Mol Biol Rep. 2020 Apr;47(4):2763-2769. doi: 10.1007/s11033-020-05378-7. Epub 2020 Mar 16. Mol Biol Rep. 2020. PMID: 32180084
-
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16. Br J Cancer. 2009. PMID: 19088722 Free PMC article.
-
Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.Fam Cancer. 2010 Dec;9(4):519-23. doi: 10.1007/s10689-010-9361-6. Fam Cancer. 2010. PMID: 20567915
-
BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families.Fam Cancer. 2006;5(1):15-20. doi: 10.1007/s10689-005-2571-7. Fam Cancer. 2006. PMID: 16528604 Review.
-
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.Klin Onkol. 2019 Summer;32(Supplementum2):51-71. doi: 10.14735/amko2019S51. Klin Onkol. 2019. PMID: 31409081 Review. English.
Cited by
-
Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.Fam Cancer. 2017 Apr;16(2):173-179. doi: 10.1007/s10689-016-9942-0. Fam Cancer. 2017. PMID: 27796713 Free PMC article.
-
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.Ecancermedicalscience. 2016 Mar 8;10:626. doi: 10.3332/ecancer.2016.626. eCollection 2016. Ecancermedicalscience. 2016. PMID: 27110282 Free PMC article. Review.
-
Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.BJOG. 2022 Jan;129(1):e16-e34. doi: 10.1111/1471-0528.16896. Epub 2021 Oct 20. BJOG. 2022. PMID: 34672090 Free PMC article.
-
Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography.Breast Cancer Res Treat. 2015 Jul;152(1):87-94. doi: 10.1007/s10549-015-3448-6. Epub 2015 Jun 3. Breast Cancer Res Treat. 2015. PMID: 26037256 Free PMC article.
-
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31. Clin Cancer Res. 2017. PMID: 28143870 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous